Search Results for:Crystal Tse

China’s biotech startup I-Mab said to target up to $500m in IPO

More than 10 biotech companies have applied to begin trading on the Hong Kong stock exchange since the bourse changed its rules in April to allow unprofitable drug developers to join.


Chinese restaurant chain Haidilao to seek approval for $1b IPO

A $1 billion deal would be the largest consumer IPO this year in Hong Kong, which has been focused on transforming itself into a hub for fundraising by new-economy companies


Cryptocurrency miner Bitmain exploring $3b Hong Kong IPO

A successful listing would be a landmark event for the crypto industry, which is increasingly trying to move from the fringes of finance into the mainstream.


Hong Kong’s new listing rules attract two more biotech startups

Suzhou Kintor Pharmaceuticals Inc. and Frontier Biotechnologies are planning Hong Kong stock offerings that could each raise about $300 million.


Hong Kong battles market slump with massive summer IPO haul

Companies including Xiaomi Corp. and China Tower Corp. have completed $19.2 billion of first-time share sales since the beginning of June


Former Jefferies banker Zhu said to join I-Mab BioPharma ahead of planned IPO

I-Mab has attracted capital from some China’s most active private equity investors including Hony Capital, Hopu Investment Management and Hillhouse Capital.


Shanghai medical device maker Microport weighing HK IPO for unit

A wider range of health-care companies are planning to list in Hong Kong after the city’s bourse relaxed rules earlier this year to allow IPOs from pre-profit biotech firms.


China Tower said to draw Hillhouse, Alibaba to Hong Kong IPO

Hillhouse funds and Taobao China Holding Ltd. are among the 10 firms that agreed to buy about $1.4 billion of stock as cornerstone investors


Niu, Chinese electric scooter startup, in talks to raise $300m in US IPO

Chinese startups continue to seek stock offerings in the U.S. even as the Hong Kong bourse has started attracting a wider range of tech and health-care firms


Ascletis draws GIC as cornerstone investor for first pre-profit biotech IPO in Hong Kong

GIC has agreed to buy $75 million of stock.